Composite inorganic adjuvant as well as preparation method and application thereof
The composite inorganic adjuvant prepared by co-precipitation of aluminum and manganese elements solves the adverse reactions and single function problems caused by aluminum adjuvant, improves the antigen delivery and immune stimulation effects, and achieves a safer and more efficient vaccine preparation.
Patent Information
- Application Number
- CN202410582645.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-12
AI Technical Summary
Existing aluminum adjuvants may cause adverse reactions after vaccine injection, such as redness, swelling and fever at the injection site, and aluminum salts may lead to neurotoxicity after entering the human body, and their functions are single and lack diversity.
Develop a composite inorganic adjuvant containing aluminum and manganese elements, prepared by co-precipitation of aluminum and manganese ions to form microparticles with a particle size distribution of 0.2-120μm, combining magnesium hydroxide, zinc hydroxide, magnesium oxide, and oxidation. Components such as zinc are prepared by simple room temperature to improve antigen adsorption and immune stimulation effects.
It achieves higher antigen delivery efficiency, enhances the immune response, reduces the dosage of aluminum adjuvant, improves the safety and immune stimulation effect of vaccine preparations, and is simple in process and is suitable for large-scale production.
Smart Images

Figure CN118924889A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immune adjuvants, and in particular to a composite inorganic adjuvant and a preparation method and application thereof. Background Art
[0002] Aluminum adjuvant is one of the best immune adjuvants currently verified by the market. It mainly provides the basis for antigen adsorption through the hydroxyl groups on the surface of aluminum hydroxide adjuvant. When the antigen and adjuvant have opposite charges, electrostatic attraction plays an important role. When the antigen contains a phosphate group, the phosphate group and the hydroxyl group on the surface of the aluminum adjuvant undergo ligand exchange, inducing changes in the protein conformation, making it easy for the phosphate group to react with the aluminum ions on the surface to form an inner sphere complex. The adsorption mechanism of protein antigens without phosphate groups and aluminum adjuvants is mainly electrostatic adsorption. Among the three forces, electrostatic adsorption is the most common, and ligand exchange is the strongest. In addition, aluminum phosphate (hydroxyaluminum phosphate complex) can also be used as an adjuvant.
[0003] However, aluminum adjuvant vaccines can cause some adverse reactions after injection, such as redness, swelling, and fever at the injection site. After entering the human body, aluminum salts will first be deposited in the brain, producing neurotoxic effects, manifested as memory loss, inattention, language dysfunction, etc. Therefore, the dosage should be controlled during use. The WHO recommends that the maximum aluminum content should not exceed 1.25 mg / dose.
[0004] The existing aluminum adjuvants available on the market mainly play the function of antigen delivery and have a single efficacy. Combined with the toxic and side effects of aluminum itself, adjuvants with simple preparation processes, superior effects and diverse functions need to be developed. Summary of the invention
[0005] In view of the above-mentioned defects of the prior art, one of the objects of the present invention is to provide a composite inorganic adjuvant and a preparation method and application thereof.
[0006] To achieve the above objectives, the first objective of the present invention is to provide a composite inorganic adjuvant, wherein the composite inorganic adjuvant comprises aluminum and manganese, and the composite inorganic adjuvant is prepared by coprecipitation of aluminum ions and manganese ions.
[0007] The valence state of the manganese element in the composite inorganic adjuvant is trivalent and / or tetravalent.
[0008] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-120 μm.
[0009] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm, 100-105 μm, 105-110 μm, 110-115 μm, 115-120 μm,.
[0010] Furthermore, the D50 of the composite inorganic adjuvant microparticles is 0.2-50 μm.
[0011] Furthermore, the D50 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm.
[0012] Furthermore, the D90 of the composite inorganic adjuvant microparticles is 0.2-100 μm.
[0013] Furthermore, the D90 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm.
[0014] Furthermore, the composite inorganic adjuvant also includes one or more components selected from the group consisting of magnesium hydroxide, zinc hydroxide, magnesium oxide, and zinc oxide.
[0015] The second object of the present invention is to provide a method for preparing a composite inorganic adjuvant, which comprises the steps of adding an alkaline solution to a solution containing the aluminum ions and manganese ions until the pH of the solution is 7.0 to 14.0, and continuously stirring.
[0016] After adjusting the pH to 7.0-14.0, continue stirring for 0.5-48 hours.
[0017] Furthermore, the preparation method comprises one or more of the following steps a) to h):
[0018] a) The concentration of the manganese ions in the solution is 1 to 2600 mM.
[0019] Preferably, the concentration of the manganese ions in the solution is 10-1500 mM.
[0020] b) The molar ratio of the manganese ion to the aluminum ion is (0.1-10):1.
[0021] Preferably, the molar ratio of the manganese ions to the aluminum ions is (0.2-5):1.
[0022] c) The manganese ions are from soluble manganese salts, which are selected from one or more of manganese chloride, manganese sulfate, manganese nitrate, manganese chlorate, potassium manganate, hydrated manganese chloride, and hydrated manganese sulfate.
[0023] Preferably, the manganese ions are from one or more of manganese chloride and hydrated manganese chloride.
[0024] d) The aluminum ion is selected from soluble aluminum salts and hydrates thereof. The soluble aluminum salt is selected from one or more of aluminum chloride, aluminum sulfate, and aluminum nitrate.
[0025] e) Further, the alkaline solution is selected from any one of sodium hydroxide, potassium hydroxide, ammonia water, sodium bicarbonate, and ethylenediamine.
[0026] f) Further, the solution containing manganese ions also contains one or both of zinc ions and magnesium ions.
[0027] Furthermore, the zinc ions or magnesium ions are from soluble zinc salts or magnesium salts. The soluble zinc salts are selected from zinc chloride, zinc nitrate, zinc chloride, zinc sulfate, and zinc acetate. The soluble magnesium salts are selected from magnesium chloride, magnesium nitrate, magnesium sulfate, and magnesium chromate.
[0028] g) After adjusting the pH to 7.0-14.0, continue stirring for 0.5-2h.
[0029] The third object of the present invention is to provide a composite inorganic adjuvant, comprising an aluminum adjuvant and manganese dioxide.
[0030] Specifically, the manganese dioxide is adsorbed or bound to the aluminum adjuvant.
[0031] Specifically, the proportion of the aluminum adjuvant surface covered by manganese dioxide is less than 100%.
[0032] Furthermore, the aluminum adjuvant is aluminum hydroxide, alum, aluminum oxyhydroxide, aluminum phosphate, Imject TM AlumAdjuvant, Alhydrogel TM , Adju-Phos TM , AlhydroVetTM One of them.
[0033] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-120 μm.
[0034] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm, 100-105 μm, 105-110 μm, 110-115 μm, 115-120 μm,.
[0035] Furthermore, the D50 of the composite inorganic adjuvant microparticles is 0.2-50 μm.
[0036] Furthermore, the D50 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm.
[0037] Furthermore, the D90 of the composite inorganic adjuvant microparticles is 0.2-100 μm.
[0038] Furthermore, the D90 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm.
[0039] Furthermore, the molar ratio of the manganese ion to the aluminum adjuvant is (0.1-10):1.
[0040] The fourth object of the present invention is to provide a method for preparing a composite inorganic adjuvant, comprising:
[0041] Aluminum adjuvant is added to the solution containing manganese ions, and the pH of the solution is adjusted to 7.0-14.0.
[0042] Furthermore, the pH of the solution is adjusted to 8.0-12.0.
[0043] Furthermore, the preparation method comprises one or more of the following steps a) to h):
[0044] a) The concentration of the manganese ions in the reaction system is 1 to 2600 mM.
[0045] Preferably, the concentration of the manganese ions in the reaction system is 10-1000 mM.
[0046] b) The molar ratio of the manganese ion to the aluminum adjuvant is (0.1-10):1.
[0047] Preferably, the molar ratio of the manganese ion to the aluminum adjuvant is (0.2-5):1.
[0048] c) The manganese ions are derived from soluble manganese salts.
[0049] The soluble manganese salt is selected from any one of manganese chloride, manganese sulfate, manganese nitrate, manganese chlorate and potassium manganate.
[0050] Preferably, the manganese ions are derived from manganese chloride.
[0051] d) The aluminum adjuvant is selected from aluminum hydroxide, alum, aluminum phosphate, Imject TM Alum Adjuvant, Alhydrogel TM , Adju-Phos TM , AlhydroVet TM One of them.
[0052] e) adding alkaline solution or alkaline buffer solution dropwise to the reaction system to adjust the pH of the reaction system solution.
[0053] Furthermore, the alkaline solution is selected from any one of sodium hydroxide, potassium hydroxide, ammonia water, sodium bicarbonate, and ethylenediamine.
[0054] f) Further, the solution containing manganese ions also contains one or both of zinc ions and magnesium ions.
[0055] Furthermore, the zinc ions or magnesium ions are from soluble zinc salts or magnesium salts. The soluble zinc salts are selected from zinc chloride, zinc nitrate, zinc chloride, zinc sulfate, and zinc acetate. The soluble magnesium salts are selected from magnesium chloride, magnesium nitrate, magnesium sulfate, and magnesium chromate.
[0056] g) The reaction system is continuously stirred during the reaction process.
[0057] h) After adjusting the pH to 7.0-14.0, continue stirring for 0.5-48 hours.
[0058] The fifth object of the present invention is to provide a composite inorganic adjuvant, comprising a manganese compound-containing microparticle core and an aluminum compound on its surface.
[0059] Specifically, the manganese-containing compound particles are slightly soluble or insoluble in water.
[0060] Specifically, the manganese-containing compound particles contain trivalent manganese and / or tetravalent manganese compounds.
[0061] Furthermore, the compound containing tetravalent manganese is selected from manganese dioxide and trimanganese tetraoxide.
[0062] Furthermore, the aluminum compound includes one or more of aluminum hydroxide, aluminum oxyhydroxide, aluminum phosphate, and an amorphous aluminum compound.
[0063] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-120 μm.
[0064] Furthermore, the particle size distribution of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm, 100-105 μm, 105-110 μm, 110-115 μm, 115-120 μm,.
[0065] Furthermore, the D50 of the composite inorganic adjuvant microparticles is 0.2-50 μm.
[0066] Furthermore, the D50 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm.
[0067] Furthermore, the D90 of the composite inorganic adjuvant microparticles is 0.2-100 μm.
[0068] Furthermore, the D90 of the composite inorganic adjuvant micron particles is 0.2-1 μm, 1-5 μm, 5-10 μm, 10-15 μm, 15-20 μm, 20-25 μm, 25-30 μm, 30-35 μm, 35-40 μm, 40-45 μm, 45-50 μm, 55-60 μm, 60-65 μm, 65-70 μm, 70-75 μm, 75-80 μm, 80-85 μm, 85-90 μm, 90-95 μm, 95-100 μm.
[0069] A sixth object of the present invention is to provide a method for preparing a composite inorganic adjuvant, comprising:
[0070] The step of uniformly mixing the aluminum ion solution and the manganese-containing compound, and slowly adding an alkaline solution under stirring to adjust the pH of the reaction solution to 7.0-14.0.
[0071] Furthermore, the method further comprises the step of adjusting the pH value of the solution and reacting at room temperature for 0.5 to 20 hours.
[0072] Furthermore, the reaction time can be selected to be 6 to 20 hours.
[0073] Furthermore, the aluminum ion solution is selected from soluble aluminum salts and hydrates thereof. The soluble aluminum salt is selected from one or more of aluminum chloride, aluminum sulfate, and aluminum nitrate.
[0074] Furthermore, the molar ratio of the aluminum ion to the manganese-containing compound is (0.1-10):1.
[0075] Furthermore, the molar ratio of the aluminum ion to the manganese-containing compound is (0.2-5):1.
[0076] Furthermore, the alkaline solution is selected from any one or more of sodium hydroxide, potassium hydroxide, ammonia water, sodium bicarbonate, and ethylenediamine.
[0077] The seventh object of the present invention is to provide a vaccine preparation comprising a composite inorganic adjuvant and an antigen.
[0078] Furthermore, the vaccine is a subunit vaccine, an inactivated vaccine or a virus-like particle vaccine.
[0079] Specifically, the vaccine includes a polyvalent pneumococcal conjugate vaccine, a hepatitis B vaccine, acellular diphtheria-tetanus-pertussis vaccine, a diphtheria-tetanus-acellular pertussis vaccine (DTaP), a type b Haemophilus influenzae conjugate vaccine, etc. Among them, a polyvalent pneumococcal conjugate vaccine is preferred, comprising a complex formed by covalently linking a plurality of serotypes of pneumococcal capsular polysaccharides and a carrier protein, wherein the pneumococcal capsular polysaccharide serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 18C, 19F, 19A, and 23F, and the carrier protein includes DT, TT, and CRM197.
[0080] Specifically, the composite inorganic adjuvant is mixed with an antigen, and the antigen is adsorbed on the surface of the composite inorganic adjuvant.
[0081] Specifically, the antigens include tumor antigens, viral antigens, and bacterial antigens.
[0082] Furthermore, the tumor antigens include tumor lysates, tumor-associated antigens (embryonic proteins, glycoprotein antigens, squamous cell antigens, etc.), tumor neoantigens and tumor markers, etc.
[0083] Furthermore, the viral antigen is selected from one or more of a novel coronavirus antigen, an HIV antigen, a Mycobacterium tuberculosis antigen, a malaria antigen, a human papillomavirus antigen or a tumor-associated antigen.
[0084] The eighth object of the present invention is to provide a use of a composite inorganic adjuvant in preventing tumor recurrence.
[0085] The ninth object of the present invention is to provide an application of a composite inorganic adjuvant in preventing infectious diseases.
[0086] The tenth object of the present invention is to provide a vaccine preparation comprising a composite inorganic adjuvant.
[0087] Furthermore, the vaccine preparation also includes an antigen.
[0088] Furthermore, the vaccine is a subunit vaccine, an inactivated vaccine or a virus-like particle vaccine.
[0089] Specifically, the vaccine includes a polyvalent pneumococcal conjugate vaccine, a hepatitis B vaccine, acellular diphtheria-tetanus-pertussis vaccine, a diphtheria-tetanus-acellular pertussis vaccine (DTaP), a type b Haemophilus influenzae conjugate vaccine, etc. Among them, a polyvalent pneumococcal conjugate vaccine is preferred, comprising a complex formed by covalently linking a plurality of serotypes of pneumococcal capsular polysaccharides and a carrier protein, wherein the pneumococcal capsular polysaccharide serotypes include 1, 3, 4, 5, 6A, 6B, 7F, 9V, 18C, 19F, 19A, and 23F, and the carrier protein includes DT, TT, and CRM197.
[0090] Specifically, the composite inorganic adjuvant is mixed with an antigen, and the antigen is adsorbed on the surface of the composite inorganic adjuvant.
[0091] Specifically, the antigens include tumor antigens, viral antigens, and bacterial antigens.
[0092] Furthermore, the tumor antigens include tumor lysates, tumor-associated antigens (embryonic proteins, glycoprotein antigens, squamous cell antigens, etc.), tumor neoantigens and tumor markers, etc.
[0093] Furthermore, the viral antigen is selected from one or more of a novel coronavirus antigen, an HIV antigen, a Mycobacterium tuberculosis antigen, a malaria antigen, a human papillomavirus antigen or a tumor-associated antigen.
[0094] The present invention has the following beneficial effects:
[0095] 1) Compared with the hydrothermal method and other methods, the preparation method of the composite inorganic adjuvant with the traditional aluminum adjuvant as the core of the present invention can realize the product preparation at room temperature, has lower process difficulty, greatly reduces the use of auxiliary materials, has good controllability, is suitable for large-scale production, and has few product impurities and is easy to separate and purify. The obtained product has a relatively uniform morphology and particle size distribution, thereby ensuring the quality of the product.
[0096] 2) The composite inorganic adjuvant prepared with aluminum source and manganese source as raw materials described in the present invention has a higher hydroxide content and has better antigen adsorption effect than the simple aluminum adjuvant, and the antigen delivery efficiency is greatly improved. At the same time, the manganese ions in the composite inorganic adjuvant can stimulate the STING pathway and amplify the immune response.
[0097] 3) The preparation method of the composite inorganic adjuvant using aluminum source and manganese source as raw materials of the present invention is simple, does not require strict operations such as temperature control, has good controllability, and can meet mass production requirements.
[0098] 4) During the preparation process, ultrasound can increase the pores on the surface of the product in the microstructure, thereby enhancing the ability to adsorb antigens, improving antigen loading efficiency, and reducing the relative dosage of adjuvants, thereby improving safety of use.
[0099] 5) The composite inorganic adjuvant prepared by the preparation method of the present invention has an amorphous manganese compound in the product, and has a better immunostimulatory effect than other manganese compounds with a clear crystal form.
[0100] 6) By introducing metal ions such as zinc or magnesium during the preparation process, inorganic particles composited with various metal oxides can be obtained, which can stimulate various immune-related signal pathways and further enhance the immune effect, thereby obtaining similar or better immune stimulation effects while reducing the amount of aluminum used.
[0101] 7) The composite inorganic adjuvant described in the present invention combines the antigen adsorption capacity of aluminum adjuvant and the immunostimulatory capacity of manganese, has a significantly improved synergistic effect, induces strong humoral and cellular immune responses, and significantly improves the potency of traditional aluminum adjuvants, thereby greatly reducing the amount of aluminum adjuvant used in vaccine preparations and improving the safety of vaccine products. BRIEF DESCRIPTION OF THE DRAWINGS
[0102] In order to make the content of the present invention more clearly understood, the present invention is further described in detail below according to specific embodiments of the present invention in conjunction with the accompanying drawings, wherein:
[0103] Figure 1 is a surface charge statistics diagram of the product in Example A2;
[0104] Figure 2 is a scanning electron microscope image of the product in Example A2, showing the microscopic morphology of the product;
[0105] Figure 3 is the full XPS spectrum of the product of Example A2.2;
[0106] Figure 4 This is a partial enlarged view of the XPS spectrum of the product of Example A2.2;
[0107] Figure 5 is the XRD pattern of the product prepared in Example A2.2;
[0108] Figure 6 is a surface charge statistics diagram of the product in Example B2;
[0109] Figure 7 is a scanning electron microscope image of the product in Example B2, showing the microscopic morphology of the product;
[0110] Figure 8 is the full XPS spectrum of the product of Example B2.2;
[0111] Fig. 9 This is a partial enlarged view of the XPS spectrum of the product of Example B2.2;
[0112] Fig.10 is the XRD pattern of the product prepared in Example B2.2;
[0113] Fig.11 is a surface charge statistics diagram of the product in Example C2;
[0114] Fig.12 is a scanning electron microscope image of the product in Example C2, showing the microscopic morphology of the product, wherein the ratio of the raw materials is Al:Mn=1:1;
[0115] Fig.13is the test result of Example D1.1, i.e., a statistical graph of protein adsorption rates of samples of different groups prepared in Example A1;
[0116] Fig.14 is a statistical graph of protein adsorption rates of samples of different groups prepared in Example B2;
[0117] Fig.15 is a statistical diagram of the proportion of mature myeloid dendritic cells in different groups in Example D2;
[0118] Fig.16 The percentage of FITC-positive BMDCs in BMDCs detected by flow cytometry after the myeloid dendritic cells of each group in Example D3 were co-incubated with the sample for 6 hours;
[0119] Fig.17 This is a statistical graph of the average intensity of the fluorescence signal in the myeloid dendritic cells detected by flow cytometry after the myeloid dendritic cells of each group were phagocytosed and co-incubated with the sample for 6 hours in Example D3;
[0120] Fig.18 This is a statistical graph of OVA-specific IgG antibody titers in the peripheral blood of mice at different times after the second immunization;
[0121] Fig.19 is a statistical graph of the detection of OVA tetramers in the spleens of mice in different groups in Example E2;
[0122] Fig. 20 This is a statistical diagram of the proportion of mature cells in myeloid dendritic cells detected by flow cytometry after the myeloid dendritic cells of each group in Example F1 were phagocytosed and co-incubated with the sample for 6 hours. DETAILED DESCRIPTION
[0123] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0124] In order to describe the technical solution of the above invention in more detail, specific embodiments are listed below to demonstrate the technical effect; it should be emphasized that these embodiments are used to illustrate the present invention but are not limited to the scope of the present invention.
[0125] As shown in this specification and claims, unless the context clearly indicates an exception, the words "a", "an", "an" and / or "the" do not refer to the singular and may also include the plural, unless the context clearly indicates an exception. The terms "include" and "comprise" only indicate that the elements that have been clearly identified are included, and these elements do not constitute an exclusive list. The device may also include other elements. The term "one embodiment" means "at least one embodiment"; the term "another embodiment" means "at least one other embodiment". The relevant definitions of other terms will be given in the following description.
[0126] As described in this specification, microparticles or micron particles refer to compound particles with a particle size of micrometers. Unless otherwise specified, manganese-containing compound microparticles may refer to manganese-containing compounds with a particle size between 0.1-1000μm, and composite inorganic adjuvant micron particles may refer to composite inorganic adjuvants with a particle size between 0.1-1000μm.
[0127] The detection equipment and methods used in the embodiments of this specification are:
[0128] Zeta potential, DLS: Nano ZS90, Nanoparticle size and Zeta potential instrument
[0129] ICP-MS: Jena M90, Germany
[0130] SEM Scanning Electron Microscope: Zeiss G500
[0131] XRD: German Bruker D8 Discover
[0132] Flow cytometer: BD C6 Plus Flow Cytometer
[0133] Example A1: A composite inorganic adjuvant micron particle, comprising aluminum and manganese, is prepared by co-precipitation of aluminum ions and manganese ions.
[0134] Embodiment A2: A method for preparing the composite inorganic adjuvant microparticles described in Embodiment A1, comprising the following steps:
[0135] (a1) Prepare 1 mol / L MnSO with deionized water. 4 Solution, 1 mol / L AlCl 3 solution, 10 mol / L NaOH solution.
[0136] (a2) According to the different mass ratios of Al:Mn, AlCl 3 Solution and MnSO 4 The solutions were mixed and stirred for 15 min to make the reaction solution fully mixed;
[0137] (a3) While stirring, slowly add 10 mol / L NaOH solution to adjust the pH of the reaction solution to 11, and react at room temperature for 6 to 24 hours;
[0138] (a4) After the reaction is completed, the reaction solution is centrifuged at 10,000 rpm for 2 min, and the supernatant is removed to obtain the product, namely, the composite inorganic adjuvant microparticles described in Example A1.
[0139] The molar ratio in step (a2) is statistically as follows:
[0140] Example No. <![CDATA[Molar ratio (AlCl 3 : MnSO 4 )]]> Example A2.1 1:0.2 Example A2.2 1:0.5 Example A2.3 1:1
[0141] For example, patent CN114028559A discloses an aluminum-manganese composite nanocrystal and its preparation method and application, wherein an aluminum-manganese composite adjuvant is prepared by aluminothermic reaction, and aluminum ion and manganese ion raw materials are heated to react with the help of an anion auxiliary agent to obtain a solid reactant. The obtained product is a composite of manganese tetraoxide crystal and AlO(OH) crystal.
[0142] Compared with patent CN114028559A, the preparation method of Example A2 is simpler, the reaction conditions are mild, no anionic additives are needed to assist crystal formation, the product purity is higher, the subsequent purification processing steps are simplified, and the safety of the final preparation is easier. In addition, the product components are different and have different immune adjuvant effects.
[0143] Example A3: Characterize the product prepared in Example A2.
[0144] The product prepared in Example A2 was characterized, including element content, surface charge, particle size distribution, micromorphology, crystal valence state, etc., and its physicochemical properties were studied. The specific analysis is as follows:
[0145] 1) Zeta potential: Take a small amount of composite inorganic adjuvant and dilute it in ultrapure water. Take 1 ml of the diluted composite inorganic adjuvant and put it into the potential cell for detection. For particle size detection, put the diluted composite inorganic adjuvant into the particle size analyzer detection cell, read the data multiple times and take the average value. The results are as follows: Figure 1 As shown, the surfaces of the products with different feed ratios are all positively charged. Usually, most protein antigens have negative charges on their surfaces. Therefore, the surfaces of the products with different feed ratios are all positively charged, which can meet the needs of adsorbing antigens. As the amount of manganese in the raw material increases, the surface positive charge of the product increases, that is, the ability to adsorb negatively charged protein antigens increases. This shows that the product prepared in Example A1 has good adsorption capacity for negatively charged protein antigens and can meet the needs of immune adjuvants for delivering antigens.
[0146] 2) The metal element content in the product was determined by inductively coupled plasma (ICP). The sample was digested with freshly prepared aqua regia, and the ion content in the sample was detected by ICP-MS. The ratio of the two metal elements in the product sample was calculated. The test results are shown in the following table:
[0147] Example No. Detect the molar ratio of two metal elements (Al:Mn) Example A2.1 1:0.2 Example A2.2 1:0.5 Example A2.3 1:0.7
[0148] The ratio of elements in the detected product can reflect the yield to a certain extent. The precipitation efficiency of aluminum ions in an alkaline environment is high, and it can be basically converted into aluminum adjuvant products such as aluminum hydroxide or aluminum oxyhydroxide. If the ratio of aluminum and manganese elements in the product is closer to the feed ratio, it means that the yield of the raw material in the preparation process is higher. The ratio of the two metal elements in the product in Examples A2.1 and A2.2 is consistent with the feed ratio, indicating that its yield is close to 100%. In addition, in Example A2.3, the concentration of manganese ions in the raw material increases, and the content of manganese in the product is slightly lower than the feed ratio compared to aluminum. But overall, the yield of the preparation method in Example A2 is higher, that is, the preparation method is efficient. In theory, if alkaline solution or alkaline buffer is continued to be added during the preparation process of A2.3, a higher conversion rate can be achieved.
[0149] 3) Scanning electron microscopy was used to examine the microscopic morphology of the products of Example A2.1 to Example A2.3. The results are as follows: Figure 2 As shown, the results show that the product size is relatively uniform, with a particle size of about 2 to 6 μm, an irregular solid surface, and a granular overall morphology. The uneven surface morphology increases the specific surface area, which is more conducive to the adsorption of antigenic substances such as proteins, increases the loading capacity, and has higher application potential.
[0150] 4) The particle size distribution was detected by dynamic light scattering method. The results are shown in the following table. D50 is about 1.5-2 μm, and the particle size is basically no more than 50 μm. In general, the particle size of the composite inorganic adjuvant prepared in Example A2.1 to Example A2.3 is more dependent on the particle size of the aluminum adjuvant in the raw material. The overall particle size distribution is 1-3 μm. If the particle size of the aluminum adjuvant in the raw material increases, the particle size of the product increases accordingly.
[0151] Example No. D10(μm) D50(μm) D90(μm) Example A2.1 1.684 2 910 15.02 Example A2.2 1.350 2.576 12.78 Example A2.3 1.529 2.388 15.25
[0152] 5) The product prepared in Example A2.2 was freeze-dried and the valence state of the metal elements was characterized by XPS. The results were as follows: Figure 3 and Figure 4 As shown, Figure 3The full spectrum is obtained by comparative analysis to obtain the distribution of metal elements in different valence states. The results show that the product contains manganese and aluminum elements, among which the valence state of aluminum is trivalent, and manganese has multiple valence states, including trivalent manganese and tetravalent manganese. The relevant spectrum of manganese element is enlarged for analysis ( Figure 4 ), it can be calculated that trivalent manganese and tetravalent manganese account for approximately 30.48% and 69.52% respectively.
[0153] 6) The product prepared in Example A2.2 was freeze-dried, and the crystal form of the compound in the product was analyzed by XRD. Figure 5 It is the XRD spectrum of the product prepared in Example A2.2. By comparing with the standard XRD spectrum of aluminum hydroxide and aluminum oxyhydroxide crystals, the existence form of aluminum is most likely aluminum hydroxide rather than aluminum oxyhydroxide. In addition, the existence form of the manganese compound is not clear. The manganese in the product obtained in Example A2.2 is amorphous manganese dioxide. The results of Example F1 show that amorphous manganese dioxide has a strong ability to stimulate the maturation of dendritic cells compared to crystalline manganese dioxide. Therefore, the composite inorganic adjuvant of the present invention has a stronger immunostimulatory effect, and is more potent as a vaccine adjuvant. It is expected that the vaccine effect can be guaranteed while reducing the dosage used, thereby improving the safety of adjuvant use.
[0154] Example B1: A composite inorganic adjuvant micron particle, comprising an aluminum adjuvant core and manganese dioxide on the surface thereof.
[0155] Example B2: The method for preparing the composite inorganic adjuvant microparticles described in Example B1 is based on a reaction similar to the mineralization reaction of a commercial aluminum adjuvant, comprising the following steps:
[0156] (b1) 1. Prepare 1 mol / L MnSO with deionized water. 4 solution, 10 mol / L NaOH solution.
[0157] (b2) Press AlCl 3 :MnSO 4 Alum (Thermo, Al content is 13.8 mg / mL) and MnSO were added in different molar ratios. 4 The solution is mixed and stirred;
[0158] (b3) While stirring, slowly add 10 mol / L NaOH solution to adjust the pH of the reaction solution to 11, and react at room temperature for 1.5-2 h;
[0159] (b4) After the reaction is completed, the reaction solution is centrifuged at 10,000 rpm for 2 min, and the supernatant is removed to obtain the product, which is the composite inorganic adjuvant micron particle.
[0160] The product can be resuspended in deionized water and stored at 4°C.
[0161] The molar ratio in step (b2) is statistically as follows:
[0162] Example No. <![CDATA[Molar ratio (AlCl 3 : MnSO 4 )]]> Example B2.1 1:0.2 Example B2.2 1:0.5 Example B2.3 1:1
[0163] Example B3: Characterization of the product prepared in Example B2
[0164] The product prepared in Example B2 was characterized, including element content, surface charge, particle size distribution, micromorphology, crystal valence state, etc., and its physicochemical properties were studied. The specific analysis is as follows:
[0165] 1) Zeta potential: Take a small amount of composite inorganic adjuvant and dilute it in ultrapure water. Take 1 ml of the diluted composite inorganic adjuvant and put it into the potential cell for detection. For particle size detection, put the diluted composite inorganic adjuvant into the particle size analyzer detection cell, read the data multiple times and take the average value. The results are as follows: Figure 6 As shown, the comparative example is a commercial aluminum hydroxide adjuvant, and the surfaces of the products with different feed ratios are all positively charged, meeting the demand for adsorbing antigens; with the increase of the amount of manganese in the raw material, the surface positive charge of the product decreases, which can reflect that with the increase in the amount of manganese fed, its coverage on the surface of the aluminum adjuvant is increasing. On the one hand, it shows that the conversion efficiency of the preparation method is high and the preparation process is highly controllable. On the other hand, the data show that the product prepared in Example B1 can meet the demand for antigen delivery by immune adjuvant.
[0166] 2) The manganese content in the product was determined by inductively coupled plasma (ICP). The sample was digested with freshly prepared aqua regia, and the manganese ion content in the sample was detected by ICP-MS. Compared with the feed amount, the conversion rate of manganese in the product sample was calculated. The test results are shown in the following table:
[0167] Example No. Conversion rate of manganese Example B2.1 67.2% Example B2.2 57.0% Example B2.3 51.5%
[0168] The conversion rate of manganese in the detected product can reflect the yield. The results show that the conversion rate of manganese element is above 50%. The preparation method has a high conversion rate. Theoretically, the conversion rate can be further improved by increasing parameters such as the concentration of the basic group and the reaction time.
[0169] 3) Scanning electron microscopy was used to examine the microscopic morphology of the products of Example B2.1 to Example B2.3. The results are as follows: Figure 7As shown, the results show that the product size is relatively uniform, with a particle size of about 1 to 3 μm. The basic structure is a spherical core with irregular solids embedded on the surface. The whole is granular and has good dispersibility. The spherical core is an aluminum adjuvant, and the irregular solids on the surface are manganese compounds. As the amount of manganese added increases, more manganese-containing compounds are coated on the surface of the aluminum adjuvant. The aluminum adjuvant is mainly used to adsorb antigens. When there are too many manganese compounds, the surface of the aluminum adjuvant will be completely covered, affecting the efficiency of antigen adsorption.
[0170] 4) The particle size distribution was detected by dynamic light scattering method. The results are shown in the following table. D50 was about 2-7 μm, and the particle size was basically no more than 50 μm. In general, the particle size distribution of the composite inorganic adjuvant prepared in Example B2.1 to Example B2.3 was 1-50 μm.
[0171] Example No. D10(μm) D50(μm) D75(μm) D90(μm) Example B2.1 1.215 1.667 2.071 2.476 Example B2.2 1.349 1.712 2.011 2.653 Example B2.3 1.492 1.679 1.911 2.156
[0172] 5) The product prepared in Example B2.2 was freeze-dried and the valence state of the metal elements was characterized by XPS. The results were as follows: Figure 8 and Fig. 9 As shown, Figure 8 It is a full spectrum, and the distribution of metal elements in different valence states is obtained through comparative analysis. The results show that the valence state of aluminum is trivalent, and manganese has multiple valence states. In addition, the relevant spectrum of manganese element is enlarged and analyzed, and it is found that trivalent manganese and tetravalent manganese account for 74.21% and 25.79% respectively.
[0173] 6) The product prepared in Example B2.2 was freeze-dried, and the crystal form of the compound in the product was analyzed by XRD. Fig.10 This is the XRD pattern of the product prepared in Example B2.2, in which the crystalline form of the aluminum compound cannot overlap with the standard XRD pattern of aluminum hydroxide and aluminum oxyhydroxide. Therefore, the composite inorganic adjuvant prepared based on the commercial aluminum adjuvant has aluminum in the form of non-aluminum hydroxide crystals or aluminum oxyhydroxide crystals. In addition, the manganese compound exists in an amorphous form, and its immunostimulatory effect may be stronger than that of crystalline manganese, as illustrated by Example F1.
[0174] Example C1: A composite inorganic adjuvant micron particle, comprising a manganese dioxide core and an aluminum adjuvant on the surface thereof.
[0175] Example C2: Preparation method of composite inorganic adjuvant microparticles described in Example C1
[0176] (1) Prepare 1 mol / L MnSO with deionized water. 4 solution, 10 mol / L NaOH solution;
[0177] (2) While stirring, slowly add NaOH solution to adjust the pH of the reaction solution to 11, and react at room temperature for 6 to 20 hours; or heat the reaction (about 20 minutes to 3 hours at 50 degrees; about 10 minutes to 2 hours at 70 degrees);
[0178] (3) removing the supernatant by centrifugation to obtain precipitated manganese and quantify the amount;
[0179] (4) According to the different molar ratios of Al:Mn, AlCl 3 The solution and precipitated manganese are mixed evenly;
[0180] (5) While stirring, slowly add NaOH solution to adjust the pH of the reaction solution to 11, and react at room temperature for 6 to 20 hours;
[0181] (5) After the reaction is completed, the reaction solution is centrifuged to remove the supernatant to obtain the product, namely, the composite inorganic adjuvant microparticles described in Example C1.
[0182] The molar ratios of different Al:Mn in step (4) are as follows:
[0183] Example No. Molar ratio (Al:Mn) Example C2.1 1:0.5 Example C2.2 1:1 Example C2.3 1:2
[0184] Example C3: Characterization of the composite inorganic adjuvant microparticles prepared in Example C1
[0185] 1) Zeta potential: Take a small amount of composite inorganic adjuvant aluminum manganese adjuvant and dilute it in ultrapure water, take 1 ml of the diluted composite inorganic adjuvant aluminum manganese adjuvant and put it into the potential cell for detection. The results are as follows Fig.11 As shown in the figure, the surface of the products with different feed ratios are all positively charged, which meets the requirements for adsorbing antigens. The higher the amount of aluminum feed, the stronger the negative charge of the product, and the better the adsorption efficiency of positively charged antigens. The composite inorganic adjuvant uses the antigen adsorption effect of aluminum compounds and the immunostimulatory effect of manganese, which is expected to achieve a better immunostimulatory effect.
[0186] 2) Scanning electron microscopy was used to examine the microscopic morphology of the product of Example C2. Fig.12 As shown, the results show that the product is relatively uniform in size, with a particle size of about 1 to 5 μm, a basic granular structure, protrusions on the surface, and good dispersibility.
[0187] Example C4: Preparation of the composite inorganic adjuvant described in Example C1 by reduction method
[0188] Use deionized water to prepare KMnO 4 Solution, 1% formaldehyde solution, slowly add 1% formaldehyde solution under stirring, react at room temperature for 6 to 20 hours, centrifuge to remove the supernatant to obtain precipitated manganese and quantify it. According to the molar ratio of Al:Mn of 1:1, AlCl 3and precipitated manganese, and stirred for 15 minutes to fully mix the reaction solution; while stirring, slowly add NaOH solution to adjust the pH of the reaction solution to 11, and react at room temperature for 6 to 20 hours; after the reaction, centrifuge the reaction solution, remove the supernatant to obtain the product, that is, the composite inorganic adjuvant micron particles described in Example C1.
[0189] The obtained composite inorganic adjuvant has a potential of about +7mV. By adjusting the feed ratio, the potential of the product can be controlled, and the composite inorganic adjuvant with positive surface charge has the ability to adsorb negatively charged antigens. In addition, the composite inorganic adjuvant has an uneven surface morphology and has a good ability to load antigens. The composite inorganic adjuvant prepared in Example C4 can achieve the function of an immune adjuvant by delivering antigens and the immunostimulatory effect of manganese compounds, and combine with antigens to form a vaccine for immunological applications.
[0190] Example D: In vitro experiments verifying the immunostimulatory effect of composite inorganic adjuvants
[0191] Example D1.1: Determination of antigen (protein) adsorption rate of the product prepared in Example A2
[0192] The determination method and steps refer to the aluminum hydroxide adjuvant protein adsorption rate test in the Chinese Pharmacopoeia. The specific steps are as follows:
[0193] 1. Prepare the adjuvant samples to be tested. The adjuvant samples to be tested are shown in the table:
[0194]
[0195]
[0196] Comparative Example 1 is an aluminum adjuvant (Thermo), and Comparative Example 2 is manganese dioxide (Sigma-Aldrich, 217646).
[0197] 2. Preparation of bovine serum albumin (BSA) solution: Take an appropriate amount of bovine serum albumin, prepare it into a 10 mg / ml solution with normal saline, and adjust the pH value to 6.0-7.0.
[0198] 3. Determination of adsorption rate: Take 5 15ml centrifuge tubes, add 0.08ml, 0.16ml, 0.4ml, 0.8ml and 1.2ml of BSA solution (10mg / ml) respectively, and add physiological saline to 4.0ml. After mixing, add 1.0ml of the adjuvant to be tested to each tube and mix well. The amount of bovine serum albumin in each tube is 0.8mg, 1.6mg, 4mg, 8mg and 12mg respectively, and the aluminum content in each tube sample is 1mg.
[0199] After the tubes were placed at room temperature for 1 hour (shaken vigorously every 10 minutes), the supernatant was collected by centrifugation, and the free bovine serum albumin content in the supernatant of each tube was determined by the BCA method. The absorbance value of each tube was recorded and the protein content was calculated. The adsorption rate of each tube was calculated based on the free bovine serum albumin content of the supernatant of each tube corresponding to the total amount of bovine serum albumin. The volume of the supernatant was calculated as 5 ml.
[0200] 4. The calculation formula is: Adsorption rate (%) = [(total BSA amount - free BSA amount in supernatant) / total BSA amount] × 100%
[0201] Fig.13 The protein adsorption rate statistics of different groups of samples in Example D1.1 show that the adsorption rate at the dotted line position on the ordinate is 80%, which is the standard for the qualified adsorption rate of aluminum adjuvants in the pharmacopoeia, that is, when the protein dosage is 0.8 mg and 1.6 mg, the adsorption ratio of the adjuvant to the protein antigen should reach more than 80%, and when the protein dosage increases, the adsorption rate decreases. The antigen adsorption capacity of Comparative Examples 1 and 2 is unqualified, and the antigen adsorption rates of Examples A2.1 to A2.3 can all meet the standards specified in the pharmacopoeia.
[0202] Example D1.2: Determination of antigen adsorption capacity of the mineralized aluminum adjuvant sample prepared in Example B2
[0203] The detection method is the same as that of Example D1.1, except that the samples are from Examples B2.1 to B2.3. Fig.14 The results show that the composite inorganic adjuvants prepared with different feed ratios all meet the protein adsorption rate standards specified in the Chinese Pharmacopoeia and meet the performance requirements of adjuvants. However, commercially available adjuvants and manganese dioxide alone cannot achieve the effect of effective protein adsorption.
[0204] Example D2: In vitro experiments verify the effect of samples on stimulating the maturation of myeloid dendritic cells. Dendritic cells (DCs) are highly efficient antigen-presenting cells in the body. They differentiate into mature dendritic cells after being stimulated by certain factors or taking up antigens. Mature DCs can effectively activate B cells and T cells, mediate specific immune responses, and play a key role in immune responses. Therefore, adjuvants that can effectively stimulate DC maturation can enhance the immune response caused by vaccines.
[0205] The experimental groups are as follows:
[0206]
[0207]
[0208] The experimental operation is as follows:
[0209] Bone marrow-derived stem cells were extracted from the bone marrow of C57BL / 6 mice, and colony stimulating factor (GM-CSF) was added to promote the differentiation of stem cells into bone marrow-derived dendritic cells (BMDCs). Then, BMDCs were co-incubated with the composite inorganic adjuvant, manganese dioxide or aluminum adjuvant prepared by the preparation methods of Example A2 and Example B2, and the composition adsorbed with OVA. The aluminum content in each sample was 5 μg, the corresponding manganese content was 2.5 and 5 μg, and the OVA (chicken egg white albumin) protein content was 2 μg. After incubation for 12 hours, we detected the maturation ratio of BMDCs in different groups by flow cytometry.
[0210] Fig.15 It is a statistical diagram of the proportion of mature myeloid dendritic cells in different groups in Example D2. The results show that Examples D2.5 to D2.8 have a better effect of stimulating the maturation of myeloid dendritic cells than Example D2.3, among which the proportion of mature myeloid dendritic cells in Examples D2.6 and D2.8 is the highest, and compared with the blank control and the commercial aluminum adjuvant (Example D2.3), the proportion of mature myeloid dendritic cells is significantly enhanced, and even better than the positive control group (Comparative Example D2.9). It shows that the composite inorganic adjuvant prepared by Examples A2.2 and B2.2 has a good immunostimulatory effect, and its immunostimulatory effect is stronger in the presence of antigens.
[0211] Example D3: Verification of the efficiency of myeloid dendritic cells phagocytosing different samples.
[0212] The more antigens myeloid dendritic cells take up, the stronger the immune response they trigger. Therefore, this embodiment verifies the efficiency of different samples being engulfed by myeloid dendritic cells. On the one hand, the proportion of samples engulfed by myeloid dendritic cells in the same period of time is detected, and on the other hand, the average value of engulfed samples in the same number of myeloid dendritic cells is detected.
[0213] The experimental groups are as follows:
[0214]
[0215] Experimental method: First, the OVA protein was labeled with FITC fluorescent molecules by chemical coupling to obtain FITC-labeled OVA protein (FITC-OVA), and then the labeled OVA protein was incubated with different samples for 30 minutes to allow each group of adjuvants to fully adsorb FITC-OVA to obtain an adjuvant-antigen combination. The adjuvant-antigen combination was then added to the differentiated BMDCs obtained in advance and incubated for 6 hours. Subsequently, the percentage of FITC-positive BMDCs in the BMDCs was detected by flow cytometry to show the ability of the immune adjuvant to stimulate dendritic cells to phagocytose antigens. At the same time, the mean fluorescence intensity (MFI) of FITC in BMDCs was counted by flow cytometry to indicate the amount of antigen phagocytosis by stimulated dendritic cells.
[0216] Fig.16 This is a statistical graph of the fluorescence signal intensity of DC cells detected by flow cytometry after the myeloid dendritic cells of each group in Example D3 were co-incubated with the sample for 6 hours, reflecting the total amount of antigen phagocytized by the DC cells of each group; Fig.17 The myeloid dendritic cells of each group in Example D3 were co-incubated with the sample for 6 hours, and the average intensity statistics of the fluorescence signals in the myeloid dendritic cells of the same number were detected by flow cytometry, reflecting the average amount of antigen phagocytized by a unit number of DC cells.
[0217] The results showed that the signal of myeloid dendritic cells phagocytosing samples in Example D3.4 was the strongest, that is, the samples in this group were phagocytosed more by myeloid dendritic cells. In addition, myeloid dendritic cells in Example D3.5 also phagocytosed more samples, indicating that the combination of manganese dioxide and aluminum adjuvants can significantly improve the efficiency of DC phagocytosis of antigens and can promote more cells to phagocytize antigens. The enhancement of antigen uptake helps immune cells to further exert their immune effects, thereby enhancing the immune response.
[0218] Example E: In vivo experiments verifying the vaccine effect of composite inorganic adjuvant
[0219] Example E1: The antibody titer monitoring experiment verifies that the composite inorganic adjuvant of the present invention has an immune effect that can achieve the in vivo level.
[0220] Antibody titer is used to measure the minimum concentration (i.e., maximum dilution) required for an antibody to recognize a specific antigenic determinant. It is generally expressed as: the maximum dilution that still produces a positive result. Antibody titer is used to evaluate the level of antigen-specific antibodies produced by mice against OVA after immunization.
[0221] Experimental groups:
[0222]
[0223] Experimental method: Healthy Balb / c mice were divided into groups after adaptive feeding, with 6 mice in each group. After depilation of the back hair, immunization was performed. The specific immunization process was as follows: OVA antigen protein was mixed with aluminum adjuvant (Al(OH) 3 ), manganese dioxide (MnO 2 ), aluminum adjuvant and manganese dioxide mixture (Al(OH) 3 +MnO 2 ), the composite inorganic adjuvants prepared in Example A2.2 and Example B2.2 were mixed and incubated in a physiological saline system for 30 minutes to allow the adjuvant to fully adsorb the antigen. The adjuvant antigen composition was injected intramuscularly into mice via an insulin syringe, and the amount of OVA antigen in each group was unified to 10 μg, and the single OVA and physiological saline (Blank) group was used as the control group.
[0224] The second immunization was performed on the 7th day after the first immunization, and the antibody titer level in the peripheral blood of the mice was continuously monitored after the second immunization. The specific detection process is: the peripheral blood of the mice was centrifuged at 5000rpm for 5 minutes to separate the serum and blood cells, and the mouse serum was diluted and the OVA-specific IgG antibody level was detected by enzyme-linked immunosorbent assay (ELISA).
[0225] Fig.18 It is a statistical chart of the titer of OVA-specific IgG antibodies in the peripheral blood of mice after the second injection of immunization. The horizontal axis is the grouping, and the vertical axis is the dilution multiple of the serum. Under different dilution multiples, the presence or absence of antibodies in the serum is detected. The dilution multiple increases, and the antibodies can still be detected, indicating that the higher the antibody titer in the serum. The results show that the concentration of OVA-specific IgG antibodies contained in the peripheral blood of mice in Example E1.6 and Example E1.7 is significantly higher than that in Example E1.1 to Example E1.5. Although Example E1.3 uses a commercial aluminum adjuvant, when the amount of adjuvant and antigen is equal to that of Example E1.6 and Example E1.7, its immune effect is not as good as the composite inorganic adjuvant described in the present invention. It shows that the composite inorganic adjuvant described in the present invention has a significant improvement in the effect of immune adjuvant compared to traditional aluminum adjuvants, and it is expected that better immunostimulatory effects can be achieved at low doses. In actual use, a reduction in dosage can reduce the amount of aluminum adjuvant used and reduce the accumulation of aluminum in the body, thereby improving the safety of vaccine preparations.
[0226] From the results, it can be seen that the antibody levels of the traditional aluminum adjuvant group and the manganese dioxide group reached a peak within 2-3 weeks after immunization, and basically maintained at this level in the following weeks, and began to gradually decline in the 8th week. In Example E1.6 and Example E1.7, within the same period of time after immunization, not only a higher level of antigen-specific antibodies was produced, but also the level of antigen-specific antibodies was significantly higher than that of Al(OH) 3 、MnO 2Compared with the mixed group of the two, the highest level of antigen-specific antibodies in the aluminum-manganese adjuvant group can be maintained until the 18th week, which is much higher than that in the control group. Therefore, the aluminum-manganese adjuvant we synthesized is expected to achieve a stronger and more lasting immune effect.
[0227] Example E2: Detection of the OVA tetramer content in the spleen of immunized mice.
[0228] The tetramer can specifically bind to the TCR on T cells that recognize MHC I-OVA. In simple terms, it can show the amount of OVA-specific T cells. In other words, the more OVA tetramer-positive T cells are, the more T cells are activated by OVA-adjuvant, and the stronger the specific immune activation.
[0229] Experimental groups:
[0230]
[0231] Experimental method: Healthy Balb / c mice were divided into groups after adaptive feeding, with 4 mice in each group. After depilation of the back hair, immunization was performed. The specific immunization process was as follows: OVA antigen protein was mixed with aluminum adjuvant (Al(OH) 3 ), manganese dioxide (MnO 2 ), aluminum adjuvant and manganese dioxide mixture (Al(OH) 3 +MnO 2 ), Al@Mn, and Al-Mn were mixed and incubated in a physiological saline system for 30 minutes to allow the adjuvant to fully adsorb the antigen, thereby obtaining an adjuvant-antigen composition. The adjuvant-antigen composition was injected intramuscularly into mice via an insulin syringe, and the amount of OVA antigen in each group was unified to 10 μg, and the single OVA and physiological saline (Blank) group was used as the control group.
[0232] The second immunization was performed 7 days after the first immunization. The spleen of the mice was taken 14 days after the second immunization. OVA tetramers were used for flow cytometry detection, which specifically bind to the OVA structure on the surface of T cells. The cells were stained by flow cytometry and the OVA-specific T cells (OVA tetramers) were detected. + CD8 + CD3 + ) accounted for all T cells (CD8 + CD3 + ) ratio.
[0233] Fig.19The data are the statistical data of OVA tetramer detection in the spleen of mice of different groups in Example E2. The data show that the spleen of mice in Example E2.3 and Example E2.4 did not have corresponding cellular immune response. On the one hand, it shows that manganese dioxide itself cannot activate an effective immune system. On the other hand, the effect of traditional aluminum adjuvants in inducing cellular immunity is also very limited. However, the composite inorganic adjuvant of the present invention can effectively induce cellular immunity, which plays an important role in anti-virus and anti-tumor, and can directly attack infected or cancerous cells. Therefore, the composite inorganic adjuvant of the present invention has a very good effect on humoral immunity and cellular immunity, and is a powerful immune adjuvant.
[0234] Example F1: Amorphous manganese dioxide has better immunostimulatory effect
[0235] Manganese dioxide of different crystalline forms was prepared according to the method described in the literature (Yang, R., Guo, Z., Cai, L., Zhu, R., Fan, Y., Zhang, Y., Han, P., Zhang, W., Zhu, X., Zhao, Q., Zhu, Z., Chan, C. K., Zeng, Z., Investigation into the Phase–Activity Relationship of MnO2 Nanomaterials toward Ozone-Assisted Catalytic Oxidation of Toluene. Small 2021, 17, 2103052. https: / / doi.org / 10.1002 / smll.202103052). The preparation method of Example A2.2 was used, except that there was no AlCl in the raw material. 3 Solution. The sample and example numbers are shown in the following table:
[0236]
[0237] Different samples were co-incubated with bone marrow-derived dendritic cells, and the maturation ratio of DC cells was detected after 6 hours. Fig. 20 This is a statistical diagram of the proportion of mature cells in myeloid dendritic cells detected by flow cytometry after the myeloid dendritic cells of each group in Example F1 were phagocytosed and co-incubated with the sample for 6 hours.
[0238] The results show that the amorphous manganese dioxide prepared in Example F1.6 has a significantly better effect on stimulating DC maturation than Examples F1.2 to F1.5, and even has a better effect on stimulating DC maturation than the positive control lipopolysaccharide. This indicates that the amorphous manganese dioxide prepared by the preparation method adopted in the present invention has a better immunostimulatory effect, and the composite inorganic adjuvant formed with the aluminum adjuvant is expected to achieve a better adjuvant effect than the crystalline aluminum-manganese complex.
[0239] Obviously, the above embodiments are merely examples for clear description and are not limitations of the implementation methods.
[0240] Although the above disclosure discusses some of the invention embodiments currently considered useful through various examples, it should be understood that such details are for illustrative purposes only, and the appended claims are not limited to the disclosed embodiments. On the contrary, the claims are intended to cover all modifications and equivalent combinations that are consistent with the essence and scope of the embodiments of the present application.
[0241] Similarly, it should be noted that in order to simplify the description of the disclosure of this application and thus help understand one or more embodiments of the invention, in the above description of the embodiments of this application, multiple features are sometimes combined into one embodiment, figure or description thereof. However, this disclosure method does not mean that the features required by the object of this application are more than the features mentioned in the claims. In fact, the features of the embodiments are less than all the features of the single embodiment disclosed above.
[0242] In some embodiments, numbers describing the number of components and attributes are used. It should be understood that such numbers used in the description of the embodiments are modified by the modifiers "about", "approximately" or "substantially" in some examples. Unless otherwise specified, "about", "approximately" or "substantially" indicate that the numbers are allowed to vary by ±. Accordingly, in some embodiments, the numerical parameters used in the specification and claims are approximate values, which may vary according to the required features of individual embodiments.
[0243] Finally, it should be understood that the embodiments described in this application are only used to illustrate the principles of the embodiments of the present application. Other variations may also fall within the scope of the present application. Therefore, as an example and not a limitation, the alternative configurations of the embodiments of the present application may be considered to be consistent with the teachings of the present application. Accordingly, the embodiments of the present application are not limited to the embodiments explicitly introduced and described in the present application.
Claims
1. A composite inorganic adjuvant, characterized in that The composite inorganic adjuvant comprises aluminum and manganese elements, and the composite inorganic adjuvant is prepared by coprecipitation of aluminum ions and manganese ions.
2. The composite inorganic adjuvant according to claim 1, characterized in that The valence state of the manganese element in the composite inorganic adjuvant is trivalent and / or tetravalent.
3. The composite inorganic adjuvant according to claim 1, characterized in that The particle size distribution of the composite inorganic adjuvant is 0.2-120 μm.
4. The composite inorganic adjuvant according to claim 1, characterized in that The D50 of the composite inorganic adjuvant is 0.2-50 μm, and / or the D90 of the composite inorganic adjuvant is 0.2-100 μm.
5. The composite inorganic adjuvant according to claim 1, characterized in that The preparation method of the composite inorganic adjuvant comprises the steps of adding an alkaline solution or an alkaline buffer solution to a solution containing the aluminum ions and the manganese ions, and continuously stirring the solution until the pH value thereof is 7.0 to 14.
0.
6. The composite inorganic adjuvant according to claim 5, characterized in that The molar ratio of the aluminum ion to the manganese ion is (0.1-10):
1.
7. The composite inorganic adjuvant according to claim 5, characterized in that After adjusting the pH to 7.0-14.0, continue stirring for 0.5-48 hours.
8. A composite inorganic adjuvant, characterized in that The invention comprises an aluminum adjuvant and manganese dioxide, wherein the manganese dioxide is adsorbed or combined on the aluminum adjuvant.
9. The composite inorganic adjuvant according to claim 8, characterized in that The proportion of the aluminum adjuvant surface covered by manganese dioxide is less than 100%.
10. The composite inorganic adjuvant according to claim 8, characterized in that The aluminum adjuvant is aluminum hydroxide, alum, aluminum oxyhydroxide, aluminum phosphate, Imject TM Alum Adjuvant, Alhydrogel TM , Adju-Phos TM , AlhydroVet TM One of them.
11. A method for preparing the composite inorganic adjuvant according to claim 8, characterized in that: The method comprises the steps of adding the aluminum adjuvant into a solution containing manganese ions and adjusting the pH value of the solution to 7.0-14.
0.
12. The preparation method according to claim 11, characterized in that: The concentration of the manganese ions is 1-2600 mM.
13. The preparation method according to claim 11, characterized in that: The molar ratio of the manganese ion to the aluminum adjuvant is (0.1-10):
1.
14. A composite inorganic adjuvant, characterized in that The invention comprises manganese-containing compound particles and an aluminum compound generated on the surface of the manganese-containing compound particles through a precipitation reaction.
15. A method for preparing the composite inorganic adjuvant according to claim 14, characterized in that: preparing a manganese compound-containing microparticle dispersion system; Aluminum ions are added to a manganese compound particle dispersion system, an alkaline solution is added, and the mixture is stirred to obtain the composite inorganic adjuvant according to claim 20.
16. The method for preparing the composite inorganic adjuvant according to claim 15, characterized in that: The manganese-containing compound particles are obtained by a reduction method or a precipitation method, or are directly purchased commercially.
17. The method for preparing the composite inorganic adjuvant according to claim 15, characterized in that: The alkaline solution is selected from any one of a sodium hydroxide solution or a potassium hydroxide solution.
18. A vaccine preparation comprising the composite inorganic adjuvant according to any one of claims 1, 8, and 14.
19. The vaccine preparation according to claim 18, characterized in that The vaccine formulation also includes an antigen.
20. The vaccine preparation according to claim 19, characterized in that The antigen is selected from one or more of viral antigens, bacterial antigens, and tumor antigens.
